Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.35 |
| ▸ | P2RY12 | Q9H244 | 5/20 | 0.34 |
| ▸ | NNMT | P40261 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.33 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.31 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.31 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.31 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.31 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.31 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.31 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23211609 | 1.00 | PRMT6 (0.35) | PRMT6P2RY12NNMTADORA1PRKAB2 | |
| SCHEMBL23211641 | 0.87 | PRMT6 (0.33) | PRMT6P2RY12NNMTADORA1 | |
| SCHEMBL23225366 | 0.85 | POLB (0.46) | — | |
| SCHEMBL20535013 | 0.85 | POLB (0.46) | — | |
| SCHEMBL20535011 | 0.85 | POLB (0.46) | — | |
| SCHEMBL23211657 | 0.83 | KDM4E (0.49) | — | |
| SCHEMBL23211660 | 0.83 | KDM4E (0.49) | — | |
| SCHEMBL23225375 | 0.83 | KDM4E (0.49) | — | |
| SCHEMBL23225367 | 0.83 | KDM4E (0.49) | — | |
| SCHEMBL23211640 | 0.82 | PRMT6 (0.33) | PRMT6ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11161869-B2 | Thermally-cleavable protecting and linker groups | EVONETIX LTD. (GB) | 2021-11-02 | — | — | US | disclosed |
| US-20210107934-A1 | THERMALLY-CLEAVABLE PROTECTING AND LINKER GROUPS | SILICON VALLEY BANK | 2021-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210107934-A1 | THERMALLY-CLEAVABLE PROTECTING AND LINKER GROUPS | CTDSP1, RNGTT, SSU72 | PRMT6 3121/4885P2RY12 3900/4885NNMT 879/4885 |
| US-11161869-B2 | Thermally-cleavable protecting and linker groups | CTDSP1, RNGTT, SSU72 | PRMT6 3121/4885P2RY12 3900/4885NNMT 879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.